Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis pipeline as of December 31, 2022 (PDF 0.1 MB)

Showing 152 results
  • VDT482
    tislelizumab
    1L ESCC
    Solid Tumors Phase 3 2023 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    1L Nasopharyngeal Carcinoma
    Solid Tumors Phase 3 2023 PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    Non-small cell lung cancer (NSCLC)
    Solid Tumors Registration PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    New Indication
  • VDT482
    tislelizumab
    2L ESCC
    Solid Tumors Registration PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    Lead Indication
  • VOB560
    VOB560
    Cancers
    Hematology Phase 1
    Lead Indication
  • VPM087
    gevokizumab
    1st line Colorectal Cancer (CRC)
    Solid Tumors Phase 1 >=2026 IL1B Antagonist (Interleukin-1 beta neutralization monoclonal antibody)
    Lead Indication
  • WNT974
    WNT974 + spartalizumab
    Solid tumors
    Solid Tumors Phase 1 Porcupine inhibitor
    Lead Indication
  • WVT078
    WVT078
    Multiple myeloma
    Hematology Phase 1
    Lead Indication
  • XXB750
    XXB750
    Cardiovascular diseases
    Cardio-renal Phase 1
  • XXB750
    XXB750
    Hypertension
    Cardio-renal Phase 2 >=2026 NPR1 agonist
    Lead Indication
  • YTB323
    rapcabtagene autoleucel
    Adult ALL
    Hematology Phase 1 CD19 CART (CD19-targeted chimeric antigen receptor T-cell immunotherapy)
  • YTB323
    rapcabtagene autoleucel
    1L high-risk large B-cell lymphoma
    Hematology Phase 2 >=2026 CD19 CART (CD19-targeted chimeric antigen receptor T-cell immunotherapy)
    Lead Indication
Legend

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.